stockrow
Friday 6 November 2026
Export CSTL’s income statement to Excel — free account
Castle Biosciences, Inc.
CSTL Healthcare Diagnostics & Research
Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024.
- Revenue
- +23.9%
- EPS
- −550.0%
- Free cash flow
- +56.8%
- Total debt
- −59.9%
Quarter to September 2026, against a year earlier
32.65
1.55
−4.53%
Follow CSTL
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 41.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 7 | 5 | 2 | 1 | 4 | — | — | — |
Altman Z-Score |
6.70 | 6.74 | 5.56 | 7.59 | 13.21 | 33.28 | 6.15 | — | — |
P/S ratio |
3.28 | 2.23 | 2.68 | 4.33 | 11.45 | 20.29 | 5.69 | 1.70 | 1.70 |
Altman Z″-Score (non-manufacturers) |
6.15 | 9.07 | 7.63 | 10.19 | 11.93 | 24.00 | 7.12 | (6.93) | — |
P/FCF ratio |
39.74 | 20.25 | 0.00 | 0.00 | 0.00 | 248.40 | 48.54 | 0.00 | 0.00 |
Beneish M-Score |
(3.49) | (2.58) | (2.37) | (2.41) | 11.61 | (2.38) | (2.01) | — | — |
P/Operating CF |
41.87 | 30.38 | 31.67 | (98.92) | (387.49) | (2,956.01) | 65.66 | 95.59 | 95.59 |
P/B ratio |
2.39 | 1.62 | 1.50 | 1.49 | 2.62 | 3.06 | 3.47 | 0.00 | 0.00 |
Price to Tangible BV |
3.04 | 2.12 | 2.15 | 2.18 | 3.34 | 3.06 | 3.47 | 0.00 | 0.00 |
EV/Sales |
2.44 | 1.38 | 1.64 | 2.54 | 8.04 | 14.11 | 4.27 | 1.96 | 1.96 |
EV/EBITDA |
0.00 | 25.44 | 0.00 | 0.00 | 0.00 | 0.00 | 23.03 | 0.00 | 0.00 |
EV/Operating CF |
13.03 | 7.05 | (63.99) | (8.36) | (39.83) | 89.58 | 31.55 | (16.06) | (16.06) |
EV/FCF |
29.55 | 12.51 | (18.72) | (7.39) | (33.67) | 172.70 | 36.41 | (13.90) | (13.90) |
Quick Ratio |
4.99 | 6.97 | 5.90 | 7.81 | 13.94 | 20.24 | 7.42 | 2.46 | 1.12 |
Current Ratio |
5.26 | 7.29 | 6.20 | 8.09 | 14.21 | 20.58 | 7.63 | 2.69 | 1.28 |
Net Debt/EBITDA |
46.20 | (15.73) | 3.98 | 3.85 | 8.77 | 78.35 | (7.67) | (6.79) | (1.78) |
Debt/Assets |
1.79% | 1.95% | 0.00% | 2.98% | 1.75% | 0.00% | 20.98% | 109.35% | 0.00% |
Debt/Equity |
0.02 | 0.02 | 0.00 | 0.03 | 0.02 | 0.00 | 0.30 | (0.43) | (1.27) |
Asset Turnover |
0.62 | 0.67 | 0.49 | 0.30 | 0.21 | 0.22 | 0.73 | 2.03 | 0.85 |
Operating CF/Net income |
(2.66) | 3.56 | 0.10 | 0.62 | 0.61 | (0.96) | 2.35 | 1.21 | 0.80 |
Capex/Depreciation |
(0.98) | (3.04) | (1.99) | (0.59) | (1.02) | (3.62) | (0.41) | (0.31) | 0.00 |
Interest Coverage |
(497.79) | 15.03 | (6,179.73) | (4,285.59) | (40,079.00) | (2.48) | 1.60 | (1.69) | (13.01) |
| (5.21%) | 4.31% | (14.54%) | (16.56%) | (7.56%) | (4.11%) | 20.95% | 19.02% | 28.65% | |
| (4.35%) | 3.71% | (12.76%) | (14.76%) | (6.94%) | (3.68%) | 4.21% | (90.72%) | (95.00%) | |
ROIC |
(14.72%) | 3.13% | (28.67%) | (29.60%) | (27.78%) | (70.02%) | 40.21% | 0.00% | 0.00% |
Return on Tangible Assets |
(6.20%) | 5.04% | (21.02%) | (24.82%) | (9.25%) | (2.47%) | 2.89% | (78.67%) | (521.83%) |
Average Days of Receivables |
46.00 | 56.30 | 63.61 | 62.53 | 67.05 | 74.34 | 103.09 | 193.67 | 123.46 |
Research and Development Expense of Revenue |
15.06% | 15.67% | 24.40% | 32.77% | 31.51% | 21.16% | 14.24% | 21.30% | 32.21% |
Selling, General and Administrative Expense of Revenue |
66.62% | 60.24% | 81.97% | 104.35% | 92.19% | 76.83% | 57.54% | 72.29% | 110.37% |
Intangible Assets out of Total Assets |
0.17 | 0.20 | 0.26 | 0.28 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
13.33% | 15.15% | 23.30% | 26.50% | 23.11% | 13.26% | 2.41% | 1.29% | 0.00% |
Graham Net Nets |
0.22 | 0.38 | 0.40 | 0.41 | 0.28 | 0.32 | 0.28 | (1.19) | (1.19) |
Graham Number |
0.00 | 15.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(2.16%) | 2.44% | (9.84%) | (11.33%) | (2.89%) | (0.76%) | (3.52%) | (24.42%) | (24.42%) |
Free Cash Flow Yield |
2.52% | 4.94% | (3.27%) | (7.93%) | (2.08%) | 0.40% | 2.06% | (8.33%) | (8.33%) |
Revenue per Share |
11.88 | 11.96 | 8.20 | 5.26 | 3.74 | 3.31 | 6.04 | 11.95 | 0.83 |
Operating CF per Share |
2.22 | 2.34 | (0.21) | (1.60) | (0.76) | 0.52 | 0.82 | (6.45) | (0.73) |
Capex per Share |
(1.24) | (1.02) | (0.51) | (0.21) | (0.14) | (0.25) | (0.11) | (0.15) | 0.00 |
Free Cash Flow per Share |
0.98 | 1.32 | (0.72) | (1.81) | (0.89) | 0.27 | 0.71 | (6.60) | (0.73) |
Cash per Share |
10.33 | 10.55 | 9.07 | 9.93 | 13.11 | 21.65 | 11.52 | 2.35 | 0.07 |
Shareholders Equity per Share |
16.24 | 16.41 | 14.60 | 15.32 | 16.38 | 21.96 | 9.92 | (29.68) | (0.95) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.24 | 16.41 | 14.60 | 15.32 | 16.38 | 21.96 | 9.92 | (29.68) | (0.95) |
Free Cash Flow |
28.37 | 36.56 | (19.23) | (47.09) | (22.46) | 5.12 | 6.08 | (12.57) | (12.23) |
Working Capital |
292.42 | 310.76 | 247.97 | 256.16 | 328.86 | 408.72 | 101.39 | 11.39 | 1.46 |
Capital Expenditures |
(35.98) | (28.31) | (13.61) | (5.44) | (3.47) | (4.75) | (0.94) | (0.28) | (0.49) |
Net Current Asset Value |
253.41 | 284.75 | 233.56 | 244.11 | 302.91 | 405.96 | 82.05 | (60.84) | (18.91) |
EV/EBIT |
0.00 | 52.76 | 0.00 | 0.00 | 0.00 | 0.00 | 30.20 | 0.00 | 0.00 |
Capex to Sales |
0.10 | 0.09 | 0.06 | 0.04 | 0.04 | 0.08 | 0.02 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 85.38 | 0.00 | 0.00 | 0.00 | 0.00 | 40.26 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.38 | 0.18 | 0.27 | 0.64 | 0.36 | 0.18 | 1.11 | 0.58 | 0.21 |
Cash ROIC |
3.63% | 4.81% | (3.03%) | (7.02%) | (3.00%) | 0.62% | 2.91% | 45.57% | (220.68%) |
Accounts Receivable Turnover |
7.28 | 7.42 | 7.12 | 6.72 | 6.26 | 4.57 | 3.88 | 2.72 | 1.64 |
Accounts Payable Turnover |
5.55 | 7.01 | 6.00 | 8.80 | 6.81 | 4.89 | 4.41 | 4.13 | 3.93 |
Inventory Turnover |
7.73 | 7.49 | 7.55 | 10.67 | 7.47 | 5.61 | 6.90 | 8.93 | 8.50 |
Average Days of Payables |
96.15 | 41.84 | 83.32 | 53.95 | 58.73 | 79.07 | 93.12 | 99.98 | 80.81 |
Days of Inventory on Hand |
52.69 | 49.32 | 64.44 | 45.38 | 46.62 | 83.55 | 61.77 | 60.78 | 22.04 |
Average Receivables |
47.30 | 44.76 | 30.89 | 20.38 | 15.02 | 13.70 | 13.37 | 8.37 | 8.37 |
Average Payables |
12.81 | 8.58 | 7.50 | 3.64 | 2.32 | 1.98 | 1.66 | 1.28 | 1.28 |
Average Inventory |
9.19 | 8.04 | 5.96 | 3.00 | 2.12 | 1.73 | 1.06 | 0.59 | 0.59 |
Average Assets |
554.90 | 492.29 | 450.33 | 454.95 | 450.95 | 279.54 | 71.08 | 11.20 | 16.11 |
Average Common Equity |
463.35 | 423.55 | 395.21 | 405.45 | 413.72 | 250.40 | 14.27 | (53.44) | (53.44) |
Columns are period end dates · fundamentals updated 5 Nov 2026